CARSGEN THERAPEUTICS HOLDINGS LIMITED Funds and ETFs CARsgen Therapeutics Holdings Limited
Equities
2171
KYG1996C1006
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.45 HKD | +2.25% |
|
+21.11% | -16.15% |
| Apr. 12 | Carsgen Therapeutics To Give Cancer Drug Oral Presentation at ASCO 2024 | MT |
| Mar. 26 | CARsgen Therapeutics Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
ETFs positioned on CARsgen Therapeutics Holdings Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.19% | 4 M€ | -27.92% | ||
| 0.03% | 2 M€ | -.--% | ||
| 0.00% | 34 M€ | +2.14% | - |
CARsgen Therapeutics Holdings Ltd is a China-based investment holding company principally engaged in discovering, developing and commercializing innovative chimeric antigen receptor (CAR)-T cell therapies. The Companyâs therapies are applied in the treatment of hematological malignancies and solid tumors. The Company have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The Company conducts its businesses in China and the United States.
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
5.045
CNY
Average target price
6.662
CNY
Spread / Average Target
+32.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.15% | 401M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 2171 Stock
- Funds and ETFs CARsgen Therapeutics Holdings Limited
